Sign in
PRLD Stock Price, Chart, Stats & News
Prelude Therapeutics Incorporated
Save
255.63M
Market cap
–
Current P/E
–
Forward P/E
PRLD chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 93.06% |
Operating margin | -861.33% |
Pretax margin | -819.59% |
Net margin | -819.59% |
Effective tax rate | – |
ROA | -70.41% |
ROE | -129.98% |
D/E | 0.26x |
Interest coverage ratio | – |
PRLD valuation
P/E | – |
P/S | 14.00x |
P/B | 2.80x |
P/CF | -3.41x |
P/FCF | -3.02x |
P/OCF | -3.41x |
PEG | -0.24x |
EV multiple | -1.83x |
About
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme.
Similar securities
Based on sector and market capitalization
Report issue